Dual effects of androgens on mammary gland

被引:13
作者
Brettes, Jean-Philippe [1 ]
Mathelin, Carole [1 ]
机构
[1] CHRU, Serv Gynecol Obstet, F-67091 Strasbourg, France
关键词
androgen; aromatase; breast cancer; progesterone; receptor;
D O I
10.1684/bdc.2008.0631
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Androgens have a dual effect on mammary cells, Indeed. they have an influence on mammary cells proliferation thanks to several possible mechanisms, including their transformation into dihydrotestosterone (5 a-reductase pathway) or into estradiol (aromatase pathway) or their binding to the androgen receptor (AR) and/or to the estrogen receptor (ER). Androgen signaling, using 5 a-reductase pathway, enables the control of cell proliferation, mediated by A R. So androgen signaling plays a crucial role in breast homeostasis, negating the proliferative effects of estrogen signaling in the breast. When androgens transform into estrogens (aromatase pathway), they increase cell proliferation and mammary carcinogenesis risk, High levels of androgens and estrogens in the serum are associated with increased incidence of postmenopausal breast cancers, Genetic variations in metabolic genes (CYP11, CYP19) and in the AR gene are both involved in dual effects of androgens, Since mammary cells metabolic enzymes vary with time, aging increases the risk of breast cancer induced by estrogens and androgens, In addition, AR function can be perturbed by low doses of synthetic progestin, acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. In the future, the determination of AR expression in infiltrative breast cancer specimens and circulating androgens levels could provide additional information about hormonal dependency and prognosis of breast carcinomas.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 64 条
[1]
Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations [J].
Agoff, SN ;
Swanson, PE ;
Linden, H ;
Hawes, SE ;
Lawton, TJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (05) :725-731
[2]
The CYP19 gene and associations with a androgens and abdominal obesity in premenopausal women [J].
Baghaei, F ;
Rosmond, R ;
Westberg, L ;
Hellstrand, M ;
Eriksson, E ;
Holm, G ;
Björntorp, P .
OBESITY RESEARCH, 2003, 11 (04) :578-585
[3]
Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0
[4]
Serum testosterone levels and breast cancer recurrence [J].
Berrino, F ;
Pasanisi, P ;
Bellati, C ;
Venturelli, E ;
Krogh, V ;
Mastroianni, A ;
Berselli, E ;
Muti, P ;
Secreto, G .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (03) :499-502
[5]
MEDROXYPROGESTERONE ACETATE THERAPY IN ADVANCED BREAST-CANCER - THE PREDICTIVE VALUE OF ANDROGEN RECEPTOR EXPRESSION [J].
BIRRELL, SN ;
RODER, DM ;
HORSFALL, DJ ;
BENTEL, JM ;
TILLEY, WD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1572-1577
[6]
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer [J].
Birrell, Stephen N. ;
Butler, Lisa M. ;
Harris, Jonathan M. ;
Buchanan, Grant ;
Tilley, Wayne D. .
FASEB JOURNAL, 2007, 21 (10) :2285-2293
[7]
GROWTH-INHIBITION OF DMBA-INDUCED RAT MAMMARY CARCINOMAS BY THE ANTIANDROGEN FLUTAMIDE [J].
BOCCUZZI, G ;
TAMAGNO, E ;
BRIGNARDELLO, E ;
DIMONACO, M ;
ARAGNO, M ;
DANNI, O .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (03) :150-154
[8]
BOWERS WF, 1956, CANCER, V9, P277, DOI 10.1002/1097-0142(195603/04)9:2<277::AID-CNCR2820090212>3.0.CO
[9]
2-Q
[10]
BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO